RxDoctor Payments Data

Douglas Vanfossen, MD

Cardiovascular Disease · Westerville, OHNPI 1629039698

Payments from drug & device makers

$31,613in general payments, 2019–2025

Across 88 payments — averaging $359.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • Johnson & Johnson$13K
  • Amgen$256
  • ZOLL Circulation Inc$150
  • Cardiovascular Systems Inc.$142
  • Shockwave Medical, Inc$131
  • plus $626 from 12 others

What the payments were for

  • Speaking & faculty fees$28,60090%
  • Travel & lodging$1,0703%
  • Food & beverage$1,8256%
  • Entertainment$1180%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,613 in reported general payments places this provider in the 80th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$45,474
Medicare patients
232
Services billed
364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$296,564
XareltoRivaroxaban89$112,301
EntrestoSacubitril/Valsartan26$31,815
Repatha SureclickEvolocumab31$23,448
BrilintaTicagrelor28$13,724
Ezetimibe204$5,516
Atorvastatin Calcium474$4,430
Rosuvastatin Calcium273$3,895
Ranolazine ErRanolazine18$3,767
Losartan Potassium282$2,708
Metoprolol Succinate183$2,477
Amiodarone Hcl37$1,855
Isosorbide Mononitrate ErIsosorbide Mononitrate113$1,329
Metoprolol Tartrate247$1,291
ClopidogrelClopidogrel Bisulfate118$1,268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$71$296,564293 claims
Johnson & JohnsonXarelto$12,697$112,30189 claims
NovartisEntresto$58$31,81526 claims
AstraZenecaBrilinta$17,611$13,72428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →